Oncology

No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from...

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...

A retrospective analysis finds that patients who undergo pneumonectomy or are aged 70 years or older after receiving neoadjuvant concurrent chemoradiation therapy experience less favorable surgical outcomes. Lung cancer, particularly stage IIIA–N2 non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. The most effective treatment approach for this type...

Neoadjuvant chemoimmunotherapy, whether compared to immunotherapy alone or in combination with apatinib, may lead to increased surgical complexity while maintaining an acceptable incidence of postoperative complications, according to the results of a retrospective study. Lung cancer, specifically non-small cell lung cancer (NSCLC), is the leading cause of cancer-related deaths worldwide, accounting for nearly 85% of...

In a retrospective study, patients without a social support network had a shorter survival rate than those with support. Non-small cell lung cancer (NSCLC) continues to be a significant health issue and is a leading cause of death in many countries. Although there are promising new treatments available for certain types of lung cancer, managing...

A cohort study finds that class-switched B cells could potentially be used as a prognostic marker for non-small cell lung cancer and as a target for future therapeutic strategies. Lung cancer is a major global health concern. Significant progress has been made in treatment, with immunotherapy emerging as a recent breakthrough of great promise. The...

A screening of the differentially expressed genes based on the Gene Expression Omnibus database and further gene enrichment analysis indicates that the tyrosine kinase-binding protein TYROBP is a potential prognostic marker for multiple myeloma. Multiple myeloma is a refractory hematological cancer characterized by the malignant proliferation of plasma cells. The tyrosine kinase-binding protein TYROBP mediates...

Double-hit newly diagnosed multiple myeloma patients with minimal residual disease positivity have a poor prognosis compared to patients with minimal residual disease negativity, according to the results of a recent cohort study. Autologous stem cell transplantation (ASCT) is one of the novel therapeutic approaches that are beneficial for newly diagnosed multiple myeloma (NDMM) patients. The...

A random forest radiomics model achieved satisfactory diagnostic performance, and models based on joint CET1 and T2-weighted imaging demonstrated better performance than single-sequence models in differentiating spinal multiple myeloma from metastases.  Spinal metastases and spinal multiple myeloma have similar radiographic characteristics, making accurate differentiation a necessity for precision therapy.  This retrospective study established and assessed...